Bioheng Therapeutics US
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Bioheng Therapeutics US sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).
Bioheng Therapeutics US: 1 sponsored US clinical trial, 1 recruiting.
Bioheng Therapeutics US sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lymphoma, Lymphoblastic, with 1 trials.
Mid-pack sponsor footprint
Bioheng Therapeutics US is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
1 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Therapeutic Areas
What is open in the Bioheng Therapeutics US pipeline
1 recruiting of 1 indexed (100% open).
Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).
Top condition: Lymphoma, Lymphoblastic (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Bioheng Therapeutics US: open-pipeline peers nationwide
Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Bioheng Therapeutics US sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Bioheng Therapeutics US page
1 registered trials is a research-attention snapshot, not an endorsement of Bioheng Therapeutics US or any single study.
- 1 of Bioheng Therapeutics US's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Lymphoma, Lymphoblastic is the condition Bioheng Therapeutics US studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lymphoma, Lymphoblastic trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Bioheng Therapeutics US pipeline card: 1 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.